Molecular genetic markers of highly differentiated thyroid cancer (literature review and personal observations)
Open Access
- 20 April 2024
- journal article
- review article
- Published by Liga-Inform, Ltd. in The Ukrainian Journal of Clinical Surgery
- Vol. 90 (6) , 23-34
Abstract
Molecular genetic markers of highly differentiated thyroid cancer (literature review and personal observations)Keywords
This publication has 80 references indexed in Scilit:
- Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational studyCancer Medicine, 2022
- Bilateral follicular variant of papillary thyroid cancer with different RAS mutations detected with next‐generation sequencing: Report of an unusual case and literature reviewDiagnostic Cytopathology, 2022
- Preoperative molecular testing in thyroid nodules with Bethesda VI cytology: Clinical experience and review of the literatureDiagnostic Cytopathology, 2020
- ThyroSeq v3 for Bethesda III and IV: An institutional experienceCancer Cytopathology, 2020
- Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in ChinaCancer Medicine, 2020
- BRAF V600E Mutation is Associated with an Increased Risk of Papillary Thyroid Cancer RecurrenceWorld Journal of Surgery, 2020
- Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7‐gene panel test in 1172 thyroid FNAs deriving from different hospitals in South ItalyCancer Cytopathology, 2019
- Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate CytologyJAMA Oncology, 2019
- Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterationsCancer Cytopathology, 2018
- Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroidCancer, 2007